Recent Updates
Recently added Catalysts
ATHE Negative Sentiment Score: 35/100

Form 603 Corporations Act 2001 Section 671B Notice of initial substantial holder To Company Name/Scheme ALTERITY THERAPEUTICS LTD ACN/ARSN/ ABN 37 080 699 065 1. Details of substantial holder (1) Name JPMorgan Chase & Co

Key Takeaway: JPMorgan Chase & Co. has become a substantial holder in Alterity Therapeutics Ltd as of March 11, 2025, with a voting power of 5.13%. The total number of votes it holds is 341,554,014 ordinary shares, signifying its significant stake in the company. This status could impact company decision-making, particularly concerning shareholder meetings and votes. The acquisition details also reveal various relevant interests held by JPMorgan's affiliates, further indicating their substantial financial involvement.

Market Sentiment Analysis

CONCERNS & RISKS

  • The announcement indicates a significant level of control by JPMorgan Chase & Co., which may raise concerns regarding influence over company decisions.
  • The substantial holding represents a potential risk for minority shareholders, as large holders can dictate terms and influence shareholder votes.

Full Press Release Details

To Company Name/Scheme ALTERITY THERAPEUTICS LTD
ACN/ARSN/ ABN 37 080 699 065
1. Details of substantial
Name JPMorgan Chase & Co. and its affiliates
ACN/ARSN (if applicable) NA
holder became a substantial holder on 11/March/2025
2. Details of voting power
number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an
associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:
Class of securities (4) Number of securities Person's votes (5) Voting power (6)
Ordinary 341,554,014 341,554,014 5.13%
3. Details of relevant interests
The nature of the relevant interest the substantial holder
or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:
Holder of relevant interest Nature of relevant interest (7) Class and number of securities
JPMORGAN CHASE BANK, N.A. Securities on Loan as Agent Lender 2,000,000 (Ordinary)
J.P. MORGAN SECURITIES LLC Rehypothecation of client securities under a Prime Brokerage Agreement 12,178,800 (Ordinary)
J.P. MORGAN SECURITIES AUSTRALIA LIMITED Purchase and sales of securities in its capacity as Principal/Proprietary 327,343,414 (Ordinary)
55I, LLC In its capacity as investment manager or in various other related capacities 31,800 (Ordinary)
4. Details of present registered holders
The persons registered as holders of the securities referred to in paragraph 3 above are as follows:
Holder of relevant interest Registered holder of securities Person entitled to be registered as holder (8) Class and number of securities
JPMORGAN CHASE BANK, N.A. JPM Nominees Australia Pty Limited Various Borrowers under the Securities Lending Agreement 2,000,000 (Ordinary)
J.P. MORGAN SECURITIES LLC Citi Australia Various Clients and Custodians 12,178,800 (Ordinary)
J.P. MORGAN SECURITIES AUSTRALIA LIMITED Ecapital Nominees Pty Ltd J.P. MORGAN SECURITIES AUSTRALIA LIMITED 327,343,414 (Ordinary)
55I, LLC Not Available Various Clients and Custodians 31,800 (Ordinary)
The consideration paid for each relevant interest referred
to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is
Holder of relevant interest Date of acquisition Consideration (9) Class and number of securities
See Appendix Cash Non-cash
The reasons the persons named in paragraph 3 above are associates
of the substantial holder are as follows:
Name and ACN/ARSN (if applicable) Nature of association
J.P. MORGAN SECURITIES AUSTRALIA LIMITED Subsidiary of JPMorgan Chase & Co.
55I, LLC Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN SECURITIES LLC Subsidiary of JPMorgan Chase & Co.
JPMORGAN CHASE BANK, N.A. Subsidiary of JPMorgan Chase & Co.
The addresses of persons named in this form are as follows:
Name Address
JPMorgan Chase & Co. 383 Madison Avenue, New York, New York, NY, 10179, United States
J.P. MORGAN SECURITIES AUSTRALIA LIMITED LEVEL 18, 83-85 CASTLEREAGH STREET, SYDNEY, NSW 2000, Australia
55I, LLC One Liberty Square, Suite 200, Boston, Suffolk, MA, 02109, United States
J.P. MORGAN SECURITIES LLC 383 Madison Ave., New York, New York, NY, 10179, United States
JPMORGAN CHASE BANK, N.A. 1111 Polaris Parkway, Columbus, Delaware, OH, 43240, United States
Print name S. Seshagiri Rao Capacity Compliance Officer
Sign here /s/ S. Seshagiri Rao Date 13/March/2025
See the definition of "relevant agreement" in section
9 of the Corporations Act 2001.
Appendix: Prescribed
information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date: 13-March-2025
Company's name: ALTERITY THERAPEUTICS LTD
ISIN: AU0000043945
Date of change of relevant interests: 11-March-2025
Schedule
Type of agreement Global Master Securities Lending Agreement ("GMSLA")
Parties to agreement JPMorgan Chase Bank, N.A. (acting as agent) ("lender") and Morgan Stanley & Co. International PLC (Borrower)
Transfer date Settlement Date 03-Mar-2025
Holder of voting rights Borrower
Are there any restriction on voting rights Yes
If yes, detail The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return date (if any) None
Does the borrower have the right to return early? Yes
If yes, detail Borrower has right to return all and any equivalent securities early at any time in accordance with the lender's instructions.
Does the lender have the right to recall early? Yes
If yes, detail Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions.
Will the securities be returned on settlement? Yes
If yes, detail any exceptions No exceptions
Statement If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.

Frequently Asked Questions

When did JPMorgan Chase & Co. become a substantial holder?

JPMorgan Chase & Co. became a substantial holder on 11 March 2025.

What is the voting power of JPMorgan Chase & Co.?

JPMorgan Chase & Co. has a voting power of 5.13%.

What type of agreement does the borrower have with JPMorgan Chase?

The borrower has a Global Master Securities Lending Agreement with JPMorgan Chase.

Are there restrictions on voting rights for borrowed securities?

Yes, the borrower must follow the lender's voting instructions under certain conditions.

Can the lender recall borrowed securities early?

Yes, the lender can recall borrowed securities with appropriate notice.

Last updated: Mar 14, 2025